A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT06632600
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation
Recruiting
- Conditions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 328
- Registration Number
- NCT06625333
- Locations
- 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation
Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy
Completed
- Conditions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT06619704
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT06617793
- Locations
- 🇨🇭
Novartis Investigative Site, Bern, Switzerland
Specified Drug-use Surveillance of Fabhalta Capsules
Recruiting
- Conditions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06606314
- Locations
- 🇯🇵
Novartis Investigative Site, Shinagawa ku, Tokyo, Japan
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT06597006
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT06597019
- Locations
- 🇲🇾
Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT06581198
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸Univ Of TX MD Anderson CC, Houston, Texas, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT06562192
- Locations
- 🇺🇸
BAMF Health, Grand Rapids, Michigan, United States
🇮🇱Novartis Investigative Site, Tel Aviv, Israel
Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT06558097
- Locations
- 🇺🇸
Novartis Investigative Site, Cypress, California, United States
© Copyright 2024. All Rights Reserved by MedPath